Transplantation: Does anemia correction delay kidney allograft dysfunction?

Edmund Huang; Suphamai Bunnapradist

doi:10.1038/nrneph.2012.39

Transplantation: Does anemia correction delay kidney allograft dysfunction?

Edmund Huang, Suphamai Bunnapradist

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Abstract

In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.

Original language	English (US)
Pages (from-to)	196-198
Number of pages	3
Journal	Nature Reviews Nephrology
Volume	8
Issue number	4
DOIs	https://doi.org/10.1038/nrneph.2012.39
State	Published - Apr 2012

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/nrneph.2012.39

Cite this

@article{dfd27d4ad7e740ac93f081c9b02cbbea,

title = "Transplantation: Does anemia correction delay kidney allograft dysfunction?",

abstract = "In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.",

author = "Edmund Huang and Suphamai Bunnapradist",

year = "2012",

month = apr,

doi = "10.1038/nrneph.2012.39",

language = "English (US)",

volume = "8",

pages = "196--198",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Transplantation

T2 - Does anemia correction delay kidney allograft dysfunction?

AU - Huang, Edmund

AU - Bunnapradist, Suphamai

PY - 2012/4

Y1 - 2012/4

N2 - In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.

AB - In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84859001193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859001193&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2012.39

DO - 10.1038/nrneph.2012.39

M3 - Short survey

C2 - 22371244

AN - SCOPUS:84859001193

SN - 1759-5061

VL - 8

SP - 196

EP - 198

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 4

ER -

Transplantation: Does anemia correction delay kidney allograft dysfunction?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this